Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Paradigm Biopharmaceuticals Ltd has seen a notable increase in its share price and trading volume, though it reports no undisclosed information that could explain this market activity. The company attributes the interest to its recent submission of a revised Phase 3 clinical trial protocol to the FDA for a knee osteoarthritis treatment, with regulatory responses expected soon. Additionally, they anticipate progress on their application for provisional approval in Australia, marking significant steps in their regulatory journey.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
